Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| OCUL | PRESS-RELEASE | bullish | 6/10 | Ocular Therapeutix announced FDA alignment to submit an NDA for AXPAXLI in wet AMD in Q4 2026 based on SOL-1 efficacy/sa | Jun 17, 2026 |
| GELS | PRESS-RELEASE | neutral | 3/10 | Gelteq provided a corporate update on its pipeline progress, including plans to commence a human clinical trial in Q3 20 | Jun 17, 2026 |
| CANF | PRESS-RELEASE | neutral | 3/10 | Can-Fite BioPharma announced its participation in the BIO International Convention 2026 (June 22-25) to conduct partneri | Jun 17, 2026 |
| SLXN | PRESS-RELEASE | neutral | 2/10 | Silexion Therapeutics, a clinical-stage biotech micro-cap ($2M market cap) developing RNAi therapies for KRAS-driven can | Jun 16, 2026 |
| TRIB | PRESS-RELEASE | bullish | 6/10 | Trinity Biotech reported Q1 2026 revenue of $10.8M, up 43% YoY from $7.6M, with gross margin improving to 35.4% from 25. | Jun 16, 2026 |
| ENTX | PRESS-RELEASE | neutral | 5/10 | Entera Bio reported positive preclinical data at ENDO 2026 for two oral peptide programs: EB612 (hypoparathyroidism) sho | Jun 16, 2026 |
| OTLK | PRESS-RELEASE | bullish | 7/10 | Outlook Therapeutics announced FDA acceptance of its resubmitted BLA for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet AM | Jun 16, 2026 |
| BIOA | PRESS-RELEASE | neutral | 3/10 | BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 (NLRP3 inhibitor) | Jun 16, 2026 |
| IVVD | PRESS-RELEASE | neutral | 5/10 | Invivyd announced completion of enrollment in its Phase 3 LIBERTY trial comparing VYD2311 (monoclonal antibody) against | Jun 16, 2026 |
| HCWB | PRESS-RELEASE | bullish | 6/10 | HCW Biologics reported positive preliminary Phase 1 data for HCW9302 in alopecia areata: all three patients in the secon | Jun 16, 2026 |
| AVTX | PRESS-RELEASE | bullish | 5/10 | Avalo Therapeutics announced advancement of AVTX-010, a next-generation anti-IL-1β monoclonal antibody, with an IND subm | Jun 16, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech priced a dilutive public offering of 22.7M shares at $3.75/share, expected to raise ~$85M, alongside a concurre | Jun 16, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech priced a dilutive public offering of 22.7M shares at $3.75/share, raising ~$85M in gross proceeds, with an addi | Jun 15, 2026 |
| RYTM | PRESS-RELEASE | bullish | 6/10 | Rhythm Pharmaceuticals presented positive clinical and real-world data at ENDO 2026 for setmelanotide and bivamelagon ac | Jun 15, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber announced an exclusive worldwide IP license agreement with Project LightShift for quantum photonic array t | Jun 15, 2026 |
| OPK | PRESS-RELEASE | neutral | 3/10 | OPKO Health presented preclinical data for OPK8801001, a long-acting hGH receptor antagonist for acromegaly, at ENDO 202 | Jun 15, 2026 |
| LFCR | PRESS-RELEASE | bullish | 6/10 | Lifecore Biomedical announced a new commercial manufacturing agreement with an unnamed global pharmaceutical company for | Jun 15, 2026 |
| AXSM | PRESS-RELEASE | neutral | 3/10 | Axsome Therapeutics presented new data on AXS-12 and solriamfetol at SLEEP 2026, including cognitive/functional outcomes | Jun 15, 2026 |
| PHVS | PRESS-RELEASE | bullish | 7/10 | Pharvaris presented positive Phase 3 RAPIDe-3 data at EAACI 2026, showing deucrictibant achieved a median time to onset | Jun 15, 2026 |
| CNTX | PRESS-RELEASE | bullish | 7/10 | Context Therapeutics reported positive interim Phase 1 data for its CLDN6 x CD3 TCE bispecific antibody, CTIM-76, showin | Jun 15, 2026 |
| FENC | PRESS-RELEASE | neutral | 2/10 | Fennec Pharmaceuticals granted 10,000 incentive stock options to a new non-executive employee at $9.00 per share under i | Jun 15, 2026 |
| AAPG | PRESS-RELEASE | mixed | 6/10 | Ascentage Pharma presented 17 clinical updates at EHA2026, including eight posters, for olverembatinib (third-generation | Jun 14, 2026 |
| ZYME | PRESS-RELEASE | bullish | 6/10 | Zymeworks presented Phase 1 dose-escalation data for ZW191, an FRα-targeting ADC, at ESMO Gynaecological Cancers Congres | Jun 14, 2026 |
| CRNX | PRESS-RELEASE | bullish | 6/10 | Crinetics presented positive Phase 2 CAH data at ENDO 2026 showing atumelnant reduced androstenedione by 67% at week 12 | Jun 14, 2026 |
| CRNX | PRESS-RELEASE | bullish | 6/10 | Crinetics presented two-year open-label extension data at ENDO 2026 showing that once-daily oral PALSONIFY (paltusotine) | Jun 14, 2026 |
| CLDX | PRESS-RELEASE | bearish | 6/10 | Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07 by 10.8%. The press release focuses on positive long | Jun 14, 2026 |
| UPB | PRESS-RELEASE | bullish | 7/10 | Upstream Bio presented positive responder analyses from the Phase 2 VIBRANT trial of verekitug in CRSwNP at EAACI 2026, | Jun 14, 2026 |
| CLDX | PRESS-RELEASE | bullish | 7/10 | Celldex presented positive Phase 1 data for CDX-622, a bispecific antibody targeting SCF and TSLP, at EAACI. The drug sh | Jun 14, 2026 |
| LEGN | PRESS-RELEASE | bullish | 7/10 | Legend Biotech presented first-in-human proof-of-concept data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T ther | Jun 14, 2026 |
| ASND | PRESS-RELEASE | bullish | 7/10 | Ascendis Pharma announced sustained efficacy and safety data from the Phase 3 PaTHway Trial of TransCon PTH (YORVIPATH) | Jun 13, 2026 |